These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 1440334)

  • 1. [The effect of pathogenetic therapy on the expression of endogenous intoxication in patients with chronic glomerulonephritis].
    Rumiantsev ISh; Kaznacheeva IG; Abdiadilova LV; Kozlov VV
    Ter Arkh; 1992; 64(6):35-9. PubMed ID: 1440334
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [A clinico-morphological analysis of the efficacy of therapy in chronic glomerulonephritis using prednisone, a cytostatic, an anticoagulant and an antiaggregant].
    Ratner MIa; Fedorova ND
    Urol Nefrol (Mosk); 1996; (2):32-5. PubMed ID: 8677550
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The catamnestic assessment of the efficacy of combined pathogenetic therapy in patients with different clinico-morphological variants of chronic glomerulonephritis].
    Ratner MIa; Serov VV; Varshavskiĭ VA; Biriukova LS; Stenina II
    Ter Arkh; 1990; 62(6):42-6. PubMed ID: 2218925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Comparison of two cyclophosphamide treatment regimens in nephrotic patients with chronic glomerulonephritis].
    Krasnova TN; Shilov EM; Tareeva IE; Gordovskaia NB; Lavrova ON; Miroshnichenko NG; Troepol'skaia OV; Ivanova LV; Ivanov AA
    Ter Arkh; 1998; 70(6):14-7. PubMed ID: 9695216
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Therapeutic effect of cyclophosphamide in patients with chronic glomerulonephritis with nephrotic syndrome].
    Duman VL
    Ter Arkh; 2002; 74(6):39-41. PubMed ID: 12136481
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [State of the blood prekallikrein-kallikrein system in patients with glomerulonephritis as affected by pathogenetic therapy].
    Petrun' NM; Pyrig LA; Krimkevich EI
    Ter Arkh; 1985; 57(6):84-6. PubMed ID: 3852551
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Sandimmun in the treatment of chronic glomerulonephritis with the nephrotic syndrome].
    Krasnova TN; Tareeva IE; Shilov EM; Mukhin NA; Miroshnichenko NG
    Ter Arkh; 1997; 69(6):21-3. PubMed ID: 9297266
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Pentoxifylline (Trental) in the treatment of chronic glomerulonephritis].
    Shoĭkhet IN; Treĭvish VS; Novikova NN
    Ter Arkh; 1986; 58(8):71-3. PubMed ID: 3764765
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [New approaches to therapy in glomerulonephritis patients].
    Riabov SI; Rakitianskaia IA; Stavskaia VV; Nikitina NA
    Ter Arkh; 1996; 68(6):24-7. PubMed ID: 8771678
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effects of cyclophosphamide on the length of remission in patients suffering from glomerulonephritis with nephrotic syndrome].
    Duman VL; Shkerina LI; Shilov EM
    Klin Med (Mosk); 2005; 83(10):48-50. PubMed ID: 16320847
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effects of pathogenetic therapy on blood cholesterol in patients with glomerulonephritis].
    Neverov NI; Stavrovskaia EV; Kolina IB; Shvetsov MIu; Zakharova EV; Shilov EM
    Ter Arkh; 2001; 73(6):37-40. PubMed ID: 11521519
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Possibilities for treating patients with the idiopathic nephrotic syndrome].
    Belovezhdov N
    Vutr Boles; 1985; 24(4):55-63. PubMed ID: 4072170
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [A comparative evaluation of the efficacy of treatment methods in chronic glomerulonephritis].
    Riabov SI; Stavskaia VV; Sheveleva LA
    Ter Arkh; 1990; 62(9):91-7. PubMed ID: 2281418
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [A clinico-pathogenetic approach to choosing the therapeutic procedure in chronic glomerulonephritis].
    Tov NL; Sidorova LD; Valentik MF; Movchan EA; Savitskaia IV; Nekipelova VI; Dorofeev SB; Nesina IA
    Ter Arkh; 1990; 62(6):37-42. PubMed ID: 2218924
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Features of lipid peroxidation in the blood of patients with chronic glomerulonephritis at the stage of renal dysfunction in the presence of nephrotic syndrome].
    Tugusheva FA; Kulikova AI; Zubina IM
    Vopr Med Khim; 1993; 39(3):18-21. PubMed ID: 8333180
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The cyclophosphamide treatment of glomerulonephritis patients].
    Dorets'kyĭ VV
    Vrach Delo; 1991 Feb; (2):51-3. PubMed ID: 2058123
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Treatment of chronic glomerulonephritis with cytostatics].
    Tareeva IE; Gordovskaia NB; Gladskikh OP; Ivanov AA; Krasnova TN
    Ter Arkh; 1989; 61(6):9-14. PubMed ID: 2799726
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The course of chronic glomerulonephritis in chronic opisthorchiasis].
    Beloborodova EI; Zibnitskaia LI; Kaliuzhina EV
    Ter Arkh; 2005; 77(11):44-9. PubMed ID: 16404862
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Further study of the indications for combination cytostatic-anticoagulant-antiaggregation-corticosteroid therapy of chronic glomerulonephritis].
    Ratner MIa; Tomilina NA; Biriukova LS; Monchakovskiĭ SF
    Ter Arkh; 1985; 57(6):69-74. PubMed ID: 4071418
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The treatment of nephrotic-type chronic glomerulonephritis with Sandimmun (cyclosporin A)].
    Mukhin NA; Tareeva IE; Krasnova TN; Shilov EM; Miroshnichenko NG
    Ter Arkh; 1995; 67(8):13-5. PubMed ID: 7482320
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.